Project Grant R43HL142318

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,095,816 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The DNA Medicine Institute, Inc. to develop a 5-minute point-of-care test for measuring anti-Factor Xa activity and hemoglobin levels. This diagnostic tool aims to guide emergency management of patients on direct oral anticoagulants, enabling faster delivery of life-saving interventions such as andexanet alfa for bleeding or thrombolytics for acute ischemic...

This $225,600 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to engineer a lab-on-a-particle platform to measure platelet function. The primary objective is to design elastic hydrogel microparticles that can assess platelet adhesion, activation, aggregation, and contraction. This innovative approach seeks to improve the reliability and reproducibility of platelet function testing and potentially...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, aims to develop and validate a new diagnostic technology called MCATS (Mechano-Assisted CAS12A Tension Sensor) for rapid and accurate detection of Heparin-Induced Thrombocytopenia (HIT). The award to Emory University, with a total funding of $542,442, will run from May 1, 2025 to January 31, 2029. The project seeks to leverage the mechanical...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $297,587 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to General Fluidics Corporation to validate the performance of the AXESS system, a novel point-of-need clinical chemistry and hematology platform. The goal is to demonstrate equivalence between the AXESS system's results and those obtained from standard venous blood testing for a basic metabolic panel and complete blood count, using matched capillary and...

This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $343,203 to Cyion Technologies LLC to develop a novel in vitro electrophysiology system for high-throughput measurement of intracellular action potential (IAP) in human-derived cardiomyocytes. The system leverages a 3D nanoelectrode array (NEA) technology to enable scalable recordings of IAP signals from many individual cardiomyocytes. This...

This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $1,077,369 to Captis Diagnostics Inc., a small disadvantaged business, to develop and commercialize a proprietary Lipid Nanoprobe (LNP) system for rapid and efficient isolation of extracellular vesicles (EVs) from bodily fluids such as blood, urine, and saliva. The goal is to enable comprehensive multi-omics (genomics, epigenetics, transcriptomics, proteomics) molecular...

Levisonics Inc. was awarded a $998,857 cooperative agreement from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) for the period of March 1, 2022 through February 29, 2024. The award will support the development of an innovative non-contact platform for low volume blood coagulation analysis using a single drop of blood. The technology aims to safely and reliably assess blood clotting in neonatal, pediatric, and vulnerable adult...

The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $400,000 Project Grant to Electronic Biosciences, Inc. on Sep 20, 2024. The grant supports the development of an innovative analytical testing device to quantitatively characterize lipoprotein particles in blood. This technology will enable rapid, precise, and cost-effective measurement of lipoprotein size, concentration, and other physical properties, which are...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $288,043 to Glycodots LLC to develop a rapid diagnostic test (EPX-RDT) that can detect eosinophil peroxidase (EPX) from nasal swab samples. The goal is to create a non-invasive, point-of-care tool to diagnose and manage asthma by measuring EPX, an important biomarker associated with...

RCE Technologies, Inc. was awarded a $255,892 Small Business Innovation Research Phase I Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program to develop a proof-of-concept machine learning-based diagnostic system for detecting myocardial infarction and ischemia in real-time. The system aims to provide point-of-care clinical classification for heart attack cases using a novel, portable device integrating the awardee's proprietary external...